Titanium salan complexes displays strong antitumor properties In Vitro and In Vivo in mice

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Immel, Timo A ^a   Groth, Ulrich ^a   Huhn, Thomas ^a   Öhlschläger, Peter ^a,b  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b AACHEN UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; TITANIUM DERIVATIVE; TITANIUM SALAN COMPLEX; UNCLASSIFIED DRUG; TITANIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; UTERINE CERVIX CANCER; ANIMAL; CHEMISTRY; DISEASE MODEL; FEMALE; UTERINE CERVIX TUMOR;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; FEMALE; INHIBITORY CONCENTRATION 50; MICE; TITANIUM; UTERINE CERVICAL NEOPLASMS;

EID: 79952826833     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017869     Document Type: Article

References (30)

1. Galanski M, Jakupec MA, Keppler BK, (2005) Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem 12: 2075-2094.
2. Jakupec MA, Galanski M, Keppler BK, (2003) Tumour-inhibiting platinum complexes-state of the art and future perspectives. Rev Physiol Biochem Pharmacol 146: 1-54.
3. Coluccia M, Natile G, (2007) Trans-platinum complexes in cancer therapy. Anticancer Agents Med Chem 7: 111-123.
4. Bruijnincx PC, Sadler PJ, (2008) New trends for metal complexes with anticancer activity. Curr Opin Chem Biol 12: 197-206.
5. Jakupec MA, Galanski M, Arion VB, Hartinger CG, Keppler BK, (2008) Antitumour metal compounds: more than theme and variations. Dalton Trans pp. 183-194.
6. Desoize B, (2004) Metals and metal compounds in cancer treatment. Anticancer Res 24: 1529-1544.
7. Ott I, Gust R, (2007) Non platinum metal complexes as anti-cancer drugs. Arch Pharm (Weinheim) 340: 117-126.
8. Caruso F, Rossi M, (2004) Antitumor titanium compounds. Mini Rev Med Chem 4: 49-60.
9. Eger S, Immel TA, Claffey J, Müller-Bunz H, Tacke M, et al. (2010) Titanocene difluorides with improved cytotoxic activity. Inorg Chem 49: 1292-1294.
10. Tshuva EY, Peri D, (2009) Modern cytotoxic titanium(IV) complexes; Insights on the enigmatic involvement of hydrolysis. Coordin Chem Rev 253: 2098-2115.
11. Strohfeldt K, Tacke M, (2008) Bioorganometallic fulvene-derived titanocene anti-cancer drugs. Chem Soc Rev 37: 1174-1187.
12. Melendez E, (2002) Titanium complexes in cancer treatment. Crit Rev Oncol Hematol 42: 309-315.
13. Lummen G, Sperling H, Luboldt H, Otto T, Rubben H, (1998) Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother Pharmacol 42: 415-417.
14. Schilling T, Keppler KB, Heim ME, Niebch G, Dietzfelbinger H, et al. (1996) Clinical phase I and pharmacokinetic trial of the new titanium complex budotitane. Invest New Drugs 13: 327-332.
15. Toney JH, Marks TJ, (1985) Hydrolysis Chemistry of the Metallocene Dichlorides M(η5-C5H5)2Cl2, M = Ti, V, Zr. Aqueous Kinetics, Equilibria, and Mechanistic Implications for a New Class of Antitumor Agents. J Am Chem Soc 107: 947-953.
16. Köpf H, Grabowski S, Voigtlander R, (1981) Spectrometric and Preparative Studies on the Hydrolysis of Titanocene Dichloride. J Organomet Chem 216: 185-190.
17. Immel TA, Groth U, Huhn T, (2010) Cytotoxic titanium salan complexes: surprising interaction of salan and alkoxy ligands. Chemistry 16: 2775-2789.
18. Immel TA, Debiak M, Groth U, Bürkle A, Huhn T, (2009) Highly selective apoptotic cell death induced by halo-salane titanium complexes. ChemMedChem 4: 738-741.
19. Pisani S, Gallinelli C, Seganti L, Lukic A, Nobili F, et al. (1999) Detection of viral and bacterial infections in women with normal and abnormal colposcopy. Eur J Gynaecol Oncol 20: 69-73.
20. Gatta G, Lasota MB, Verdecchia A, (1998) Survival of European women with gynaecological tumours, during the period 1978-1989. Eur J Cancer 34: 2218-2225.
21. Giraldi T, Sava G, Bertoli G, Mestroni G, Zassinovich G, (1977) Antitumor action of two rhodium and ruthenium complexes in comparison with cis-diamminedichloroplatinum(II). Cancer Res 37: 2662-2666.
22. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, et al. (1993) Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23: 2242-2249.
23. Immel TA, Martin JT, Dürr CJ, Groth U, Huhn T, (2010) Dimethyl titanocene Y: a valuable precursor for libraries of cytotoxic titanocene derivatives. J Inorg Biochem 104: 863-867.
24. Öhlschläger P, Osen W, Dell K, Faath S, Garcea RL, et al. (2003) Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 77: 4635-4645.
25. Öhlschläger P, Pes M, Osen W, Durst M, Schneider A, et al. (2006) An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 24: 2880-2893.
26. Öhlschläger P, Quetting M, Alvarez G, Durst M, Gissmann L, et al. (2009) Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. Int J Cancer 125: 189-198.
27. Öhlschläger P, Spies E, Alvarez G, Quetting M, Groettrup M, (2011) The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. Int J Cancer 128: 473-481.
28. Perez-Regadera J, Sanchez-Munoz A, De-la-Cruz J, Ballestin C, Lora D, et al. (2010) Cisplatin-based radiochemotherapy improves the negative prognosis of c-erbB-2 overexpressing advanced cervical cancer. Int J Gynecol Cancer 20: 164-172.
29. Hamid R, Rotshteyn Y, Rabadi L, Parikh R, Bullock P, (2004) Comparison of alamar blue and MTT assays for high through-put screening. Toxicol In Vitro 18: 703-710.
30. Systat Software, Inc. 2006 (http://www.systat.com).